FDA Opioid Rulings Slammed

March 10, 2014 10:41 PM

34 0

FDA decisions about prescription opioid painkillers have been inconsistent, and the agency should make future decisions with greater transparency, according to drug safety researchers.

While all extended-release oxycodone products (OxyContin and generics) are required to have abuse-deterrent properties, that's not the case for long-acting oxymorphone (Opana and generics) or hydrocodone (Zohydro), according to Lewis Nelson, MD, of NYU School of Medicine, and colleagues.

Read more

To category page